|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2009-6-1
|
|
pubmed:abstractText |
Minimal residual disease detection, used for clinical management of children with acute lymphoblastic leukemia, can be performed by molecular analysis of antigen-receptor gene rearrangements or by flow cytometric analysis of aberrant immunophenotypes. For flow minimal residual disease to be incorporated into larger national and international trials, a quality assured, standardized method is needed which can be performed in a multi-center setting. We report a four color, flow cytometric protocol established and validated by the UK acute lymphoblastic leukemia Flow minimal residual disease group. Quality assurance testing gave high inter-laboratory agreement with no values differing from a median consensus value by more than one point on a logarithmic scale. Prospective screening of B-ALL patients (n=206) showed the method was applicable to 88.3% of patients. The minimal residual disease in bone marrow aspirates was quantified and compared to molecular data. The combined risk category concordance (minimal residual disease levels above or below 0.01%) was 86% (n=134). Thus, this standardized protocol is highly reproducible between laboratories, sensitive, applicable, and shows good concordance with molecular-based analysis.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-10648387,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-11023499,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-11069029,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-11830473,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-11877265,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-12070008,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-14981525,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-15029212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-15178999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-15295608,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-15538405,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-15690642,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-15755280,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-16184615,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-16885052,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-17301806,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-18548617,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-18780832,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-19483150,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-9492773,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-9695973,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-9716617,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-9718378,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-9834212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-9848348,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19377076-9850021
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
pubmed-author:BarnettDavidD,
pubmed-author:CaseMarianM,
pubmed-author:DaviesPaulP,
pubmed-author:EyreLisaL,
pubmed-author:GouldenNickN,
pubmed-author:HancockJeremyJ,
pubmed-author:HelliwellMargaretM,
pubmed-author:IrvingJulieJ,
pubmed-author:JessonJennyJ,
pubmed-author:JohanssonUlrikaU,
pubmed-author:KnottsLindaL,
pubmed-author:LawsonSarahS,
pubmed-author:MaceyMarionM,
pubmed-author:MintoLynneL,
pubmed-author:NoelNigelN,
pubmed-author:UK MRD steering Group,
pubmed-author:UKALL Flow MRD Group,
pubmed-author:VirgoPaulP,
pubmed-author:WhitbyLiamL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
870-4
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19377076-Antigens, CD19,
pubmed-meshheading:19377076-Antigens, CD34,
pubmed-meshheading:19377076-Child,
pubmed-meshheading:19377076-Flow Cytometry,
pubmed-meshheading:19377076-Gene Rearrangement,
pubmed-meshheading:19377076-Humans,
pubmed-meshheading:19377076-Leukemia, B-Cell,
pubmed-meshheading:19377076-Neoplasm, Residual,
pubmed-meshheading:19377076-Neprilysin,
pubmed-meshheading:19377076-Polymerase Chain Reaction,
pubmed-meshheading:19377076-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:19377076-Prognosis,
pubmed-meshheading:19377076-Prospective Studies,
pubmed-meshheading:19377076-Receptors, Antigen, T-Cell,
pubmed-meshheading:19377076-Reference Standards,
pubmed-meshheading:19377076-Reproducibility of Results,
pubmed-meshheading:19377076-Sensitivity and Specificity
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting.
|
|
pubmed:affiliation |
Northern Institute for Cancer Research, Newcastle upon Tyne, Tyne and Wear, UK. j.a.e.irving@ncl.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
